ABIVAX SA

Abivax SA: How a French biotech’s anti‑viral pipeline is riding a health‑care rotation and what clinical milestones could spark its next growth surge.

Abivax SA sees renewed investor confidence as Truist Securities issues a buy rating, backed by a strong pipeline of antiviral and therapeutic vaccines targeting high‑growth markets in Asia and Latin America.

Abivax SA successfully raised $747.5 million in capital and saw its stock price surge 586% after announcing positive Phase-3 data for its Colitis Ulcerosa treatment candidate.

Abivax SA’s stock surged by 48% after positive late-stage trial results for its ulcerative colitis treatment, obefazimod, and a significant capital increase.

Abivax SA’s stock price surged over 500% after the company announced positive results from its Phase 3 clinical trials for its ulcerative colitis drug, Obefazimod.

Abivax SA, a Paris-based biotech firm, navigates financial uncertainty while advancing its innovative pipeline of anti-viral therapies and vaccines.